Articles tagged "Post-transplant malignancy"

2016 American Transplant Congress
Thorough Pre-Transplant Evaluation and Appropriate Case Selection Is the Mainstay for Better Survival in Recipients with Malignancy.
W. Yin.^1,2
¹Surgery, School of Medicine, Tzu Chi University, Hualien, Taiwan; ²Surgery, Dalin Tzu Chi General Hospital, Chia-I, Taiwan.
IntroductionMalignancy has become one of the three major causes of death after transplantation in the past decade and is thus increasingly important in all organ…
2016 American Transplant Congress
Prostate Cancer Characteristics and Outcome in Renal Transplant Recipients: Results from a Contemporary Monocentric Study.
C. Pettenati,¹ A.-S. Jannot,² V. Verkarre,³ S. Hurel,¹ H. Kreis,⁴ M. Housset,⁵ C. Legendre,⁴ A. Méjean,¹ M.-O. Timsit.¹
¹Department of Urology and Transplant surgery, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Descartes, Paris, France; ²Department of Statistics, Computing and Public Health, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Descartes, Paris, France; ³Department of Pathology, Hôpital Necker, AP-HP, Université Paris Descartes, Paris, France; ⁴Department of Nephrology and Transplantation, Hôpital Necker, AP-HP, Université Paris Descartes, Paris, France; ⁵Department of Onco-Radiotherapy, Hôpital Necker, AP-HP, Université Paris Descartes, Paris, France.
Objective To analyze prostate cancer characteristics in a contemporary monocentric renal transplant recipients (RTR) population and to compare oncological outcome after radical prostatectomy (RP) with…
2016 American Transplant Congress
Outcomes of Solid Organ Transplant Recipients with Pre-Existing Malignancies.
S. Acuna,^1,2,3 R. Sutradhar,^1,2 J. Kim,^1,2,4 N. Baxter.^1,2,3
¹Institute of Health Policy, Management and Education, University of Toronto, Toronto, ON, Canada; ²Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; ³Department of Surgery, St. Michael's Hospital, Toronto, ON, Canada; ⁴Department of Medicine, University Health Network, Toronto, ON, Canada.
Background: Pre-transplant malignancy (PTM) is considered a relative contraindication for transplantation due to the heightened risk of cancer recurrence associated with immunosuppression. However, little has…
2015 American Transplant Congress
The Onset of Post-Transplant Malignancies Is Related to a Change in Gene Expression Profiles in Peripheral Blood Mononuclear Cells
G. Stallone,¹ R. Federica,¹ P. Pontrelli,² M. Accetturo,² A. Oranger,² M. Gigante,² G. Castellano,² A. Schena,² M. Fiorentino,² B. Infante,¹ L. Gesualdo,² G. Grandaliano.¹
¹Dept.of Surgical and Medical Sciences, Nephrology Unit, University of Foggia, Foggia, Italy; ²Dept. of Emergency and Organ Transplantation, Nephrology Unit, University of Bari, Bari, Italy.
Malignancies are the third leading cause of death in renal transplant recipients and their incidence is increasing. Although the role of the immune system in…
2015 American Transplant Congress
24 Month Post Transplantation Follow Up of the Certitem Trial
E. Rondeau,¹ E. Cassuto,² V. Vuiblet,³ C. Legendre,⁴ P. Merville,⁵ Y. Le Meur,⁶ B. Moulin,⁷ P. Westeel,⁸ B. Hurault De Ligny,⁹ A. Lécuyer,¹⁰ M. Tindel,¹¹ N. Kamar.¹²
¹Hôpital Tenon, Paris, France; ²Hôpital Pasteur, Nice, France; ³Hôpital Maison Blanche, Reims, France; ⁴Hôpital Necker, Paris, France; ⁵Hôpital Pellegrin, Bordeaux, France; ⁶Hôpital La Cavale Blanche, Brest, France; ⁷Nouvel Hôpital Civil, Strasbourg, France; ⁸Hôpital Sud, Amiens, France; ⁹CHU, Caen, France; ¹⁰Novartis Pharma S.A.S, Rueil-Malmaison, France; ¹¹Keyrus Biopharma, Levallois-Perret, France; ¹²Hôpital Rangueil, Toulouse, France.
Background: CERTITEM has evaluated the effect of everolimus/calcineurin inhibitors free (CNI free) on fibrosis progression and results have been reported at 12 months (M12). Data…
2015 American Transplant Congress
Verification of OPTN Hepatocellular Carcinoma Recurrence Data
J. George,¹ K. Eddinger,¹ D. Goldberg,² M. Levine,³ P. Abt.³
¹Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA; ²Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA; ³Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA.
PURPOSE: OPTN data on HCC recurrence is increasingly utilized for a variety of studies; however, the accuracy of this data has not been examined. We…
2015 American Transplant Congress
Cancer Mortality Among Recipients of Solid Organ Transplant in Ontario
S. Acuna,^1,2,3 K. Fernandes,⁴ C. Daly,^2,3 L. Hicks,³ R. Sutradhar,^1,4 S. Kim,^1,4 N. Baxter.^1,2,3,4
¹Institute of Health Policy, Management and Education, University of Toronto, Toronto, ON, Canada; ²Department of Surgery, St. Michael's Hospital, Toronto, ON, Canada; ³Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada; ⁴Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.
Purpose: Solid organ transplantation recipients (SOTR) have a higher risk of some cancers than the general population, but are also at high risk of mortality…
2015 American Transplant Congress
Dermatology Is an Essential Part of Transplant Care: Report of a Two-Year Experience from a Transplant Dermatology Center
E. Pritchett,¹ B. Miller,¹ A. Colasacco,¹ G. Malat,² A. Doyle,² S. Guy,³ C. Cusack,¹ C. Chung,¹ M. Abdelmalek.¹
¹Department of Dermatology, Drexel University College of Medicine, Philadelphia; ²Departent of Medicine, Drexel University College of Medicine, Philadelphia; ³Department of Surgery, Drexel University College of Medicine, Philadelphia.
Background: It is well-documented that patients who have undergone organ transplantation have a higher incidence of new skin cancers and that this risk is magnified…
2015 American Transplant Congress
Clinical Course of Pre-Existing Monoclonal Gammopathies Following Kidney Transplant
C. Johnson.
Nephrology, University of Washington, Seattle, WA.
INTRODUCTIONThe progression of monoclonal gammopathies following kidney transplant is not well described. Previous single-center retrospective data suggested that the course for a monoclonal gammopathy of…
2015 American Transplant Congress
Detecting Bowel Cancer in Pre-Dialysis, Dialysis Patients and Kidney Transplant Recipients – The DETECT Study
G. Wong, J. Chapman, J. Craig.
University of Sydney, Sydney, NSW, Australia.
Background: Colorectal cancer (CRC) is the third most common solid organ cancer in people living with kidney disease, and has a very poor prognosis, with…